Grown Rogue International (GRUSF) Capital Expenditures (2018 - 2026)
Grown Rogue International (GRUSF) recorded quarterly Capital Expenditures of $2.5 million in Q1 2026, down 100.0% quarter-over-quarter from $1056.5 billion in Q4 2025, and up 942.27% on a YoY basis from $241532.0 in Q1 2025.
Grown Rogue International (GRUSF) Capital Expenditures (2018 - 2026) Analysis & Trends
Grown Rogue International's Capital Expenditures history runs 9 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Capital Expenditures rose 942.27% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $6.9 million (up 50.07% YoY), while the FY2025 annual figure was $4.7 million, up 14.13% from the prior year.
- Capital Expenditures was $2.5 million for Q1 2026 at Grown Rogue International, down from $1056.5 billion in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1267.5 billion in Q4 2024 to a low of -$1267.5 billion in Q3 2024.
- Historically, Capital Expenditures has averaged $519968.6 across 5 years, with a median of -$263905.5 in 2024.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures tumbled 556.8% in 2023, then surged 1000503556.29% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $93905.0 in 2022, then jumped by 34.91% to $126690.0 in 2023, then soared by 1000503556.29% to $1267.5 billion in 2024, then declined by 16.65% to $1056.5 billion in 2025, then sank by 100.0% to $2.5 million in 2026.
- The last three Capital Expenditures figures came in at $2.5 million (Q1 2026), $1056.5 billion (Q4 2025), and -$1056.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 168.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 110.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 100.80 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 9.10 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 51.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.09 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 2.04 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 8.83 Mn |
| 10 | Grown Rogue International | - | - | 3.96 Mn | 2.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.52 Mn |
| Mar 31, 2026 | 2.52 Mn |
| Dec 31, 2025 | 1,056.50 Bn |
| Dec 31, 2025 | 1,056.50 Bn |
| Sep 30, 2025 | -1,056.50 Bn |
| Sep 30, 2025 | -1,056.50 Bn |
| Jun 30, 2025 | -773,726.00 |
| Jun 30, 2025 | -773,726.00 |
| Mar 31, 2025 | 241,532.00 |
| Mar 31, 2025 | 241,532.00 |
| Dec 31, 2024 | 1,267.54 Bn |
| Dec 31, 2024 | 1,267.54 Bn |
| Sep 30, 2024 | -1,267.53 Bn |
| Sep 30, 2024 | -1,267.53 Bn |
| Jun 30, 2024 | -230,497.00 |
| Jun 30, 2024 | -230,497.00 |
| Mar 31, 2024 | -297,314.00 |
| Mar 31, 2024 | -297,314.00 |
| Dec 31, 2023 | 126,690.00 |
| Dec 31, 2023 | 126,690.00 |